Greater ciprofloxacin tolerance as a possible selectable phenotype underlying the pandemic spread of the H30 subclone of Escherichia coli sequence type 131

Antimicrobial Agents and Chemotherapy
James R JohnsonEvgeni Sokurenko

Abstract

Minimum bactericidal concentrations (MBCs) for ciprofloxacin were significantly higher among 41 members of the H30 subclone within Escherichia coli sequence type 131 than among 48 other fluoroquinolone-resistant E. coli isolates. This MBC difference, which was not explained by ciprofloxacin MICs, gyrA, parC, and parE mutations, the presence of aac(6')-Ib-cr, or organic solvent tolerance (a surrogate for efflux pump activity), conceivably could have promoted the pandemic emergence of the H30 sequence type 131 subclone.

References

May 1, 1989·Antimicrobial Agents and Chemotherapy·J S WolfsonM N Swartz
Mar 25, 1998·The Journal of Antimicrobial Chemotherapy·M OethingerS B Levy
Mar 29, 2005·Antimicrobial Agents and Chemotherapy·C WiuffB R Levin
Oct 2, 2008·Emerging Infectious Diseases·Amee R MangesPierre-Paul Tellier
Oct 8, 2008·Antimicrobial Agents and Chemotherapy·Sonia K Morgan-LinnellLynn Zechiedrich
Jun 25, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·James R JohnsonMariana Castanheira
Mar 16, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Deborah A WilliamsonJoshua T Freeman
Apr 4, 2012·Emerging Infectious Diseases·James R JohnsonUNKNOWN MASTER Investigators
Jan 5, 2013·The Journal of Infectious Diseases·James R JohnsonEvgeni V Sokurenko
Mar 8, 2013·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Ritu BanerjeeJames R Johnson
Aug 9, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Aylin ColpanUNKNOWN VICTORY (Veterans Influence of Clonal Types on Resistance: Year 2011) Investigators
Apr 8, 2014·Proceedings of the National Academy of Sciences of the United States of America·Nicola K PettyScott A Beatson
Jul 2, 2014·Clinical Microbiology Reviews·Marie-Hélène Nicolas-ChanoineJean-Yves Madec

❮ Previous
Next ❯

Citations

Mar 31, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·James R JohnsonEvgeni Sokurenko
Mar 30, 2017·PloS One·Veronika TchesnokovaEvgeni V Sokurenko
Jul 3, 2019·Proceedings of the National Academy of Sciences of the United States of America·Veronika TchesnokovaEvgeni V Sokurenko
Mar 12, 2020·Frontiers in Microbiology·Miklos FuziAkos Toth
Jan 21, 2021·Antimicrobial Agents and Chemotherapy·Johannes CampWinfried V Kern

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.